With the EGFR/PI3K signaling cascade being one of the most frequently mutated pathways in lung cancer, we speculated that combined inhibition of EGFR- and PI3K/mTOR-signaling might be effective in our cell line panel of NSCLC cells. The gene discussed is EGFR; the disease is lung carcinoma.